(redirected from Beta thalassemia)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to Beta thalassemia: Alpha Thalassemia


A hereditary form of hemolytic anemia resulting from a defective synthesis of hemoglobin: thalassemia major is the homozygous state accompanied by clinical illness, and thalassemia minor is the heterozygous state and may not have evident clinical manifestations. Also known as Mediterranean anemia.



(also thalassanemia), a familial hemolytic anemia, first detected in 1925 among inhabitants of the Mediterranean region. Thalassemia is caused by disturbances in hemoglobin synthesis.

References in periodicals archive ?
Sickle cell disease patients who undergo routine transfusions exhibit a pattern that on the surface phenotypically mimics S-beta+ thalassemia, the combination of sickle disease and beta thalassemia.
Its lead project is the development of hepcidin mimetic peptides for the treatment of iron overload in diseases such as beta thalassemia and hemochromatosis.
Funding will support research into the safety and efficacy of umbilical cord stem cell transplantations to treat Beta Thalassemia Major.
The Beta Thalassemia short program for the Variant II hemoglobin testing system has been cleared for marketing by the FDA.
com, applauds a recent announcement by researchers at Nationwide Children's Hospital showing the use of parthenogenetic stem cells as a potential strategy to treat genetic diseases such as Huntington's disease, beta thalassemia or tuberous sclerosis.
Director of Blood and Marrow Transplantation at Children's Hospital & Research Center Oakland, and a leader of one of the clinical teams that will be conducting the first Phase 1 clinical trial of this ZFP Therapeutic in transfusion-dependent beta thalassemia patients.
today announced a cross-licensing and collaboration agreement to develop drugs that may prove effective in treating the genetic diseases Duchenne muscular dystrophy (DMD) and beta thalassemia.
These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs and their applications in the treatment of beta thalassemia and sickle cell disease, receipt of funds from CIRM, partnerships with collaborators and clinical trials of ZFP Therapeutics in individuals with beta-thalassemia.
Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer's disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease.
3 developed by EGT pursuant to an exclusive license agreement with Sloan Kettering Institute (SKI), will be used for MSKCC's upcoming beta Thalassemia human clinical trial.